
Dr. Maria Carolina Gallego Iradi
Ped Stem Cell Transplantation, Pediatrics - Ped Stem Cell Transplantation
Web page: http://web.stanford.edu/people/iradi
Bio
Dr. Maria Carolina Gallego Iradi earned her BSc degree in Marine Biology (UDO, Venezuela), MSc. in Waste Treatment (UIA, Spain), and a Ph.D. in Genetics working in neuroscience (Universidad de Zaragoza, Spain), all with honors. Her passage through UDO, McKnight Brain Institute, neurology, and neuroscience depts. at the University of Florida (USA) as a postdoc, researcher, and faculty member to strengthen her knowledge. Dr. Gallego Iradi also collaborated with the Aerospace Engineering dept. at the University of Florida trying to connect genetic mutations with chemical elements by lasers (LIBS) in cells and flies. Then, Stanford University (USA) consolidated her scientific research with human immunology. She is a top expert in molecular biology, neuroscience, RNA transcriptomics, and bioinformatics for gene data mining to understand insights of the human cell-organ function.
Dr. Gallego Iradi has worked and lived in different countries in Europe (Spain, Belgium, Cyprus), and North and South America (USA, Venezuela) as a chair, professor, top researcher, private founder, CEO, institutional counselor, and mentor.
She was distinguished with the Medal of Honor (Ministry of Defense) and Order of Merit “City of Porlamar” to recognize her discoveries and contribution to Nueva Esparta State (Venezuela).
Dr. Gallego Iradi is the discoverer of Alzheimer's disease pathologies and AD-related genes in dolphins (2005 during her Ph.D., published in 2017). This finding had worldwide recognition after its publication in a scientific journal and the British newspaper “The Times”. This news spread in TV, newspapers, Newsweek, The Times, CBS, Discover, Chicago Tribune, Los Angeles Times, Nature, and National Geographic Italy (2018) among others.
She is a top researcher, entrepreneur, and mentor at Silicon Valley right now.
Honors & Awards
-
Award of Merit “City of Porlamar”, Nueva Esparta State Government, Venezuela (2007)
-
Medal of Honor, Veterans Hospital-UNEFA (Department of Defense, Margarita Island, Venezuela) (2007)
-
PhD Genetics and Development, cum laude, Universidad de Zaragoza, Spain (2005)
-
MSc. Waste Management, cum laude, Universidad Internacional de Andalucia, Spain (2003)
-
BSc. Marine Biology, cum laude, Universidad de Oriente, Venezuela (1999)
Education & Certifications
-
PhD Genetics & Dev cum laude, Universidad de Zaragoza, (Zaragoza, Spain), Genetics (2005)
-
MSc. Waste Management cum laude, Universidad Internacional de Andalucia (Jaen, Spain), waste control (2004)
-
BSc. Marine Biology cum laude, Universidad de Oriente (Margarita Island, Venezuela), Biology (1999)
All Publications
-
N-terminal sequences in matrin 3 mediate phase separation into droplet-like structures that recruit TDP43 variants lacking RNA binding elements.
Laboratory investigation; a journal of technical methods and pathology
2019
Abstract
RNA binding proteins associated with amyotrophic lateral sclerosis (ALS) and muscle myopathy possess sequence elements that are low in complexity, or bear resemblance to yeast prion domains. These sequence elements appear to mediate phase separation into liquid-like membraneless organelles. Using fusion proteins of matrin 3 (MATR3) to yellow fluorescent protein (YFP), we recently observed that deletion of the second RNA recognition motif (RRM2) caused the protein to phase separate and form intranuclear liquid-like droplets. Here, we use fusion constructs of MATR3, TARDBP43 (TDP43) and FUS with YFP or mCherry to examine phase separation and protein colocalization in mouse C2C12 myoblast cells. We observed that the N-terminal 397 amino acids of MATR3 (tagged with a nuclear localization signal and expressed as a fusion protein with YFP) formed droplet-like structures within nuclei. Introduction of the myopathic S85C mutation into NLS-N397 MATR3:YFP, but not ALS mutations F115C or P154S, inhibited droplet formation. Further, we analyzed interactions between variants of MATR3 lacking RRM2 (ΔRRM2) and variants of TDP43 with disabling mutations in its RRM1 domain (deletion or mutation). We observed that MATR3:YFP ΔRRM2 formed droplets that appeared to recruit the TDP43 RRM1 mutants. Further, coexpression of the NLS-397 MATR3:YFP construct with a construct that encodes the prion-like domain of TDBP43 produced intranuclear droplet-like structures containing both proteins. Collectively, our studies show that N-terminal sequences in MATR3 can mediate phase separation into intranuclear droplet-like structures that can recruit TDP43 under conditions of low RNA binding.
View details for DOI 10.1038/s41374-019-0260-7
View details for PubMedID 31019288
-
Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy
SCIENTIFIC REPORTS
2018; 8: 4049
Abstract
To understand how mutations in Matrin 3 (MATR3) cause amyotrophic lateral sclerosis (ALS) and distal myopathy, we used transcriptome and interactome analysis, coupled with microscopy. Over-expression of wild-type (WT) or F115C mutant MATR3 had little impact on gene expression in neuroglia cells. Only 23 genes, expressed at levels of >100 transcripts showed ≥1.6-fold changes in expression by transfection with WT or mutant MATR3:YFP vectors. We identified ~123 proteins that bound MATR3, with proteins associated with stress granules and RNA processing/splicing being prominent. The interactome of myopathic S85C and ALS-variant F115C MATR3 were virtually identical to WT protein. Deletion of RNA recognition motif (RRM1) or Zn finger motifs (ZnF1 or ZnF2) diminished the binding of a subset of MATR3 interacting proteins. Remarkably, deletion of the RRM2 motif caused enhanced binding of >100 hundred proteins. In live cells, MATR3 lacking RRM2 (ΔRRM2) formed intranuclear spherical structures that fused over time into large structures. Our findings in the cell models used here suggest that MATR3 with disease-causing mutations is not dramatically different from WT protein in modulating gene regulation or in binding to normal interacting partners. The intra-nuclear localization and interaction network of MATR3 is strongly modulated by its RRM2 domain.
View details for DOI 10.1038/s41598-018-21371-4
View details for Web of Science ID 000426643600013
View details for PubMedID 29511296
View details for PubMedCentralID PMC5840295
-
Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging
ALZHEIMERS & DEMENTIA
2018; 14 (2): 195–204
Abstract
Alzheimer's disease and diabetes mellitus are linked by epidemiology, genetics, and molecular pathogenesis. They may also be linked by the remarkable observation that insulin signaling sets the limits on longevity. In worms, flies, and mice, disrupting insulin signaling increases life span leading to speculation that caloric restriction might extend life span in man. It is our contention that man is already a long-lived organism, specifically with a remarkably high postfertility life span, and that it is this that results in the prevalence of Alzheimer's disease and diabetes.We review evidence for this hypothesis that carries specific predictions including that other animals with exceptionally long postreproductive life span will have increased risk of both diabetes and Alzheimer's disease.We present novel evidence that Dolphin, like man, an animal with exceptional longevity, might be one of the very few natural models of Alzheimer's disease.
View details for DOI 10.1016/j.jalz.2017.08.014
View details for Web of Science ID 000424405500009
View details for PubMedID 28972881
-
Heterogeneity of Matrin 3 in the Developing and Aging Murine Central Nervous System
JOURNAL OF COMPARATIVE NEUROLOGY
2016; 524 (14): 2740–52
Abstract
Mutations in the MATR3 gene encoding the nucleotide binding protein Matrin 3 have recently been identified as causing a subset of familial amyotrophic lateral sclerosis (fALS) and more rarely causing distal myopathy. Translating the identification of MATR3 mutations into an understanding of disease pathogenesis and the creation of mouse models requires a complete understanding of normal Matrin 3 levels and distribution in vivo. Consequently, we examined the levels of murine Matrin 3 in body tissues and regions of the central nervous system (CNS). We observed a significant degree of variability in Matrin 3 protein levels among different tissues of adult animals, with the highest levels found in reproductive organs and the lowest in muscle. Within the adult CNS, Matrin 3 levels were lowest in spinal cord. Further, we found that Matrin 3 declines significantly in CNS through early development and young adulthood before stabilizing. As previously reported, antibodies to Matrin 3 primarily stain nuclei, but the intensity of staining was not uniform in all nuclei. The low levels of Matrin 3 in spinal cord and muscle could mean that that these tissues are particularly vulnerable to alterations in Matrin 3 function. Our study is the first to characterize endogenous Matrin 3 in rodents across the lifespan, providing the groundwork for deciphering disease mechanisms and developing mouse models of MATR3-linked ALS. J. Comp. Neurol. 524:2740-2752, 2016. © 2016 Wiley Periodicals, Inc.
View details for DOI 10.1002/cne.23986
View details for Web of Science ID 000382547400002
View details for PubMedID 26878116
View details for PubMedCentralID PMC5832027
-
Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy
PLOS ONE
2015; 10 (11): e0142144
Abstract
Mutations in Matrin 3 [MATR3], an RNA- and DNA-binding protein normally localized to the nucleus, have been linked to amyotrophic lateral sclerosis (ALS) and distal myopathies. In the present study, we have used transient transfection of cultured cell lines to examine the impact of different disease-causing mutations on the localization of Matrin 3 within cells.Using CHO and human H4 neuroglioma cell models, we find that ALS/myopathy mutations do not produce profound changes in the localization of the protein. Although we did observe variable levels of Matrin 3 in the cytoplasm either by immunostaining or visualization of fluorescently-tagged protein, the majority of cells expressing either wild-type (WT) or mutant Matrin 3 showed nuclear localization of the protein. When cytoplasmic immunostaining, or fusion protein fluorescence, was seen in the cytoplasm, the stronger intensity of staining or fluorescence was usually evident in the nucleus. In ~80% of cells treated with sodium arsenite (Ars) to induce cytoplasmic stress granules, the nuclear localization of WT and F115C mutant Matrin 3 was not disturbed. Notably, over-expression of mutant Matrin 3 did not induce the formation of obvious large inclusion-like structures in either the cytoplasm or nucleus.Our findings indicate that mutations in Matrin 3 that are associated with ALS and myopathy do not dramatically alter the normal localization of the protein or readily induce inclusion formation.
View details for DOI 10.1371/journal.pone.0142144
View details for Web of Science ID 000364032600108
View details for PubMedID 26528920
View details for PubMedCentralID PMC4631352
-
KCNC3(R420H), a K+ channel mutation causative in spinocerebellar ataxia 13 displays aberrant intracellular trafficking
NEUROBIOLOGY OF DISEASE
2014; 71: 270–79
Abstract
Spinocerebellar ataxia 13 (SCA13) is an autosomal dominant disease resulting from mutations in KCNC3 (Kv3.3), a voltage-gated potassium channel. The KCNC3(R420H) mutation was first identified as causative for SCA13 in a four-generation Filipino kindred with over 20 affected individuals. Electrophysiological analyses in oocytes previously showed that this mutation did not lead to a functional channel and displayed a dominant negative phenotype. In an effort to identify the molecular basis of this allelic form of SCA13, we first determined that human KCNC3(WT) and KCNC3(R420H) display disparate post-translational modifications, and the mutant protein has reduced complex glycan adducts. Immunohistochemical analyses demonstrated that KCNC3(R420H) was not properly trafficking to the plasma membrane and surface biotinylation demonstrated that KCNC3(R420H) exhibited only 24% as much surface expression as KCNC3(WT). KCNC3(R420H) trafficked through the ER but was retained in the Golgi. KCNC3(R420H) expression results in altered Golgi and cellular morphology. Electron microscopy of KCNC3(R420H) localization further supports retention in the Golgi. These results are specific to the KCNC3(R420H) allele and provide new insight into the molecular basis of disease manifestation in SCA13.
View details for DOI 10.1016/j.nbd.2014.08.020
View details for Web of Science ID 000342549900026
View details for PubMedID 25152487
View details for PubMedCentralID PMC4181561
-
CLONING, SEQUENCING AND EXPRESSION IN THE DOG OF THE MAIN AMYLOID PRECURSOR PROTEIN ISOFORMS AND SOME OF THE ENZYMES RELATED WITH THEIR PROCESSING
NEUROSCIENCE
2010; 171 (4): 1091–1101
Abstract
Alzheimer's disease (AD) is characterized by neuronal loss and the presence of both neurofibrillary tangles and senile plaques in the brain. These plaques arise from the deposition of beta-amyloid (Aβ) peptides (38-43 amino acids), which are generated from enzymatic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. In the present work, we cloned the principal APP isoforms as well as some enzymes that have been implicated in their amyloidogenic and non-amyloidogenic processing in dogs. Additionally, the main proteases implicated in the degradation of Aβ were also studied. We also investigated the level of expression of these APP isoforms and enzymes in different brain regions and in peripheral tissues. Our data demonstrate that these canine proteins are highly homologous to their human counterparts. In addition, the expression pattern of these proteins in dogs is consistent with previous data reported in human beings. Thus, dogs may be a natural model to study the biology of AD and could also serve as an animal model for Aβ-targeted drugs against this devastating disease.
View details for DOI 10.1016/j.neuroscience.2010.09.042
View details for Web of Science ID 000285231000011
View details for PubMedID 20875843